The Oculus Rift is taking its time to perfect for the consumer market, but if you're after a virtual-reality (VR) or augmented-reality (AR) experience, one product will provide a solution that uses your smartphone as the display.harga of Malaysia monolayerprotective products. 

Called vrAse, by Edinburgh, Scotland-based Louise Bankhead, it's a 3D-printed headset. Your smartphone slides into the front, providing the display. 

Packed inside the headset is a pair of interchangeable lenses, one for each eye. Using an app that splits your display into two separate images — what is known as side-by-side or SBS format, for which there are many existing apps — each eye then sees a slightly different version of the same image, creating an effective 3D view. 

Using content that has already been converted into SBS or converting it yourself, it can be used on pretty much any existing content,ratings of energy monitors so you can find the best casesforipad4. such as films and games — although for games, you will need a method of controlling it that isn't the phone's touchscreen, for obvious reasons. 

You can also use it with your phone's camera to record first-person video, as seen in the video below. 

There are six phones that vrAse has been built to fit perfectly: the iPhone 5, HTC One, Sony Xperia Z, Samsung Galaxy S3 and S4 and the Samsung Galaxy Note 2. It has been optimised for phones with a 5- to 6-inch screen; anything larger will be too heavy for the headset and wearer; and, if you don't have any of the "perfect fit" phones, a universal adapter will be able to accommodate your device. 

It's important to note that vrAse will not work with glasses; however, the Kickstarter page notes that you will not need your glasses, except in cases of more severe myopia, in which case you can wear contact lenses. 

A pledge of ￡58 (AU$100), plus ￡15 (AU$26) international shipping, gets you one vrAse in the colour of your choice, white or dark grey, with an estimated delivery date of February 2014. Head over to the vrAse Kickstarter page or the vrAse website for more info. 

Thanks everybody and welcome once again to the 8th Annual Citi Biotech Conference here in Boston. It's really a great pleasure to move on to very much a hot topic of biosimilars and really a very distinguished panel here with us to talk about what are the challenges and opportunities for both branded and biosimilar drug makers. 

Let me introduce, Liav Abraham, all the way on the left. You all know is the Citi Specialty Pharma and Generic Analyst. Liav is going to co-moderate the panel with me. And I would like to introduce Scott Foraker, who is the Vice President and General Manager of Biosimilars at Amgen. He is right here in the middle. 

To my immediate left is Tom Wintner,The eveningdresses that you can see on this page. who is an associate at Edwards, Wildman & Palmer, which is a law firm here in Boston and there is not a ton of attorney so far, who has really written extensively about biosimilars because this is a very new area as you can imagine and Tom actually has done quite a lot of work and I think this is really going to be one of the focus for his career. 

And then to our left is Michael [Weiss], who is Senior Consultant at Define Health, which is a strategy management consulting that’s specifically focused on biopharma. So everybody, thanks so much for coming. We really appreciate it. 

Scott, lets maybe start with you because Amgen is in very interest position that you are both kind of a defender of your branded product, but at the same time you guys really have a lot of expertise in-house, many [stats] and a partnership obviously with (inaudible) on biosimilars. 

So you have kind of a lot that you can share with us. So one, let’s discuss some of the things that we’ve seen so far is companies in the space like Teva, like Biogen and Samsung, they’ve had some setbacks at Rituxan and [Merck] is snagged and both Aranesp and Enbrel and as a result Merck is now partners with the [three] what’s known as Samsung Bioepis which is Biogen, Samsung and Merck partnership. What are some of the challenges that are facing biosimilars were trying to come to market, technological, resource capability, regulatory. 
Scott Foraker - VP and General Manager of Biosimilars, Amgen 

Thanks Yaron. So I would characterize the problems or issues or challenges really in two categories. One, technical and the other is capital. So let’s start with capital. So just to get in to this business, very capital intensive business which is going to be play some limit on those that can play, and I am talking about the developed markets primarily the U.S. and the EU where the regulatory bar will be high, the showing of biosimilarity requirement pie, and so the technical requirements are going to be very,manufactures and sell protective trucks, very challenging to show that you can have a highly similar drug. 

Of course the best you can do with the biosimilar unlike a small molecule generic product is to show that it’s similar, and how similar,Our doublesidedtape1 is imported from Latin America. similar enough is a great question that regulators are being challenged with. We are doing our best to dial with in similarity as much as possible and I think we are doing a pretty good job. But the fact of the matter is that it’s been difficult to on a 100 or more quality attributes to dial in biosimilarity and so that’s part of the technical challenge.